ALKERMES PUBLIC LIMITED COMPANY Directors’ Report and Consolidated Financial Statements For the Nine Months Ended December 31, 2013 ALKERMES PLC Table of Contents Directors’ Report ........................................................... 2 Statement of Directors’ Responsibilities .......................................... 56 Independent Auditors’ Report—Group ........................................... 57 Consolidated Profit and Loss Account ............................................ 59 Consolidated Statement of Comprehensive Income .................................. 60 Consolidated Balance Sheet ................................................... 61 Consolidated Statement of Cash Flows ........................................... 62 Consolidated Reconciliation of Shareholders’ Funds .................................. 63 Notes to the Consolidated Financial Statements .................................... 64 Independent Auditors’ Report—Company ......................................... 105 Company Balance Sheet ...................................................... 107 Notes to the Company Financial Statements ....................................... 108 1 DIRECTORS’ REPORT For the Year Ended March 31, 2013 The directors present their report and audited consolidated financial statements for the nine months ended December 31, 2013. The directors have elected to prepare the consolidated financial statements in accordance with section 1 of the Companies (Miscellaneous Provisions) Act, 2013, which provides that a true and fair view of the state of affairs and profit or loss may be given by preparing the financial statements in accordance with accounting principles generally accepted in the United States of America (‘‘U.S.’’) (‘‘GAAP’’), as defined in Section 1(1) of the Companies (Miscellaneous Provisions) Act 2013, to the extent that the use of those principles in the preparation of the financial statements does not contravene any provision of the Companies Acts or of any regulations made thereunder. On May 21, 2013, our Audit and Risk Committee, with such authority delegated to it by our Board of Directors, approved a change to our fiscal year-end from March 31 to December 31. This Directors’ Report covers the nine-month transition period ended December 31, 2013 and reflects our financial results for the nine-month period from April 1, 2013 through December 31, 2013(the ‘‘Transition Period’’). The prior period presented in this Directors’ Report covers the fiscal year ended March 31, 2013 and reflects financial results for the twelve-month period from April 1, 2012 to March 31, 2013. NOTE REGARDING TRADEMARKS CODAS↧, IPDAS↧, LinkeRx↧, MXDAS↧, NanoCrystal↧, SODAS↧, VERELAN and VIVITROL↧ are registered trademarks of Alkermes. The following are trademarks of the respective companies listed: ABILIFY and ABILIFY MAINTENA↧—Otsuka Pharmaceutical Co., Ltd.; ADALAT↧— Bayer AG Corporation; AFEDITAB↧—Actavis, Inc.; AMPYRA↧, FAMPYRA↧, ZANAFLEX and ZANAFLEX CAPSULES↧—Acorda Therapeutics, Inc.; ANTABUSE↧—Teva Women’s Health, Inc.; AUBAGIO↧—Sanofi Societe Anonyme France; AVINZA↧—King Pharmaceuticals Research and Development, Inc.; AVONEX↧, TECFIDERA and TYSABRI↧—Biogen Idec MA, Inc.; BETASERON↧—Bayer Pharma AG; BYDUREON and BYETTA↧—Amylin Pharmaceuticals, LLC; CAMPRAL↧—Merck Sante; CARDIZEM↧—Valeant International Bermuda; COPAXONE↧—Teva Pharmaceutical Industries Ltd.; DILZEM↧—Cephalon (UK) Limited or Warner-Lambert Company LLC (depending on the jurisdiction); DILTELAN↧—Elan Corporation plc or Cephalon Limited (depending on the jurisdiction); EMEND↧—Merck Sharp & Dohme Corp.; EXTAVIA↧, FOCALIN XR↧, GILENYA and RITALIN LA↧—Novartis AG; INVEGA↧ SUSTENNA↧, RISPERDAL CONSTA and XEPLION↧—Johnson & Johnson Corp. (or its affiliate); LUVOX CR↧—Abbott Laboratories; MEGACE↧—E.R. Squibb & Sons, LLC; NAPRELAN↧— Alvogen Pharma US Inc.; RAPAMUNE↧—Wyeth LLC; REBIF↧—Ares Trading S.A.; SUBOXONE↧ and SUBUTEX↧—Reckitt Benckiser Healthcare (UK) Ltd.; SUPRALIP and TRICOR↧—Fournier Industrie et Sante Corporation; UNIVER↧—various non-Alkermes entities (depending on the jurisdiction); VICTOZA↧—Novo Nordisk A/S LLC; ZOHYDRO↩—Zogenix, Inc.; and ZYPREXA↧ and ZYPREXA RELPREVV↧—Eli Lilly and Company. Other trademarks, trade names and service marks appearing in this Directors’ Report are the property of their respective owners. Principal Activities Alkermes plc (as used in this section, together with our subsidiaries, ‘‘us’’, ‘‘we’’, ‘‘our’’, or the ‘‘Company’’) is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on our own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. We have a diversified portfolio of more than 20 commercial drug products and a 2 clinical pipeline of product candidates that address central nervous system (‘‘CNS’’) disorders such as addiction, schizophrenia and depression. On September 16, 2011, the business of Alkermes, Inc. and the drug technologies business (‘‘EDT’’) of Elan Corporation, plc (‘‘Elan’’) were combined under Alkermes plc (this combination is referred to as the ‘‘Business Combination,’’ the ‘‘acquisition of EDT’’ or the ‘‘EDT acquisition’’). Our ordinary shares are listed on the NASDAQ Global Select Market, where our trading symbol is ‘‘ALKS.’’ Our principal offices are located at Connaught House, 1 Burlington Road, Dublin 4, Ireland. We have a research and development (‘‘R&D’’) center in Waltham, Massachusetts; R&D and manufacturing facilities in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington, Ohio. Business Overview Marketed Products We earn manufacturing and/or royalty revenues on net sales of products marketed by our partners and earn revenue on net sales of VIVITROL, which is a proprietary product that we manufacture, market and sell in the U.S. Our marketed products are described in the table below, including, among other things, the territory in which the marketer has the right to sell the product and the source of revenues for us: Product Indication(s) Technology Territory Revenue Source Marketer RISPERDAL Schizophrenia Extended-release Worldwide Manufacturing and Ortho-McNeil-Janssen CONSTA Bipolar I Disorder microsphere Royalty Pharmaceuticals, Inc. and Janssen Pharmaceutica International, a division of Cilag International AG (taken together, ‘‘Janssen’’) INVEGA Schizophrenia NanoCrystal United States Royalty Janssen SUSTENNA/ (U.S.) XEPLION Rest of World (‘‘ROW’’) AMPYRA/ Treatment to Oral Controlled U.S. Manufacturing and Acorda FAMPYRA improve walking Release (‘‘OCR’’) ROW Royalty Therapeutics, Inc. in patients with Matrix Drug (‘‘Acorda’’) multiple Absorption System Biogen Idec sclerosis (‘‘MS’’), (MXDAS) International GmbH as (‘‘Biogen Idec’’), under demonstrated by sublicense from Acorda an increase in walking speed BYDUREON Type 2 diabetes Extended-release Worldwide Royalty AstraZeneca plc microsphere (‘‘AstraZeneca’’) VIVITROL Alcohol Extended-release U.S. Product sales Alkermes dependence microsphere Russia and Manufacturing and Cilag GmbH Opioid dependence Commonwealth of Royalty International (‘‘Cilag’’) Independent States (‘‘CIS’’) TRICOR Cholesterol NanoCrystal Worldwide Royalty AbbVie Inc. LIPANTHYL lowering Abbott Laboratories LIPIDIL SUPRALIP (and other trade names under which fenofibrate 48 mg and 145 mg are sold) 3 Product Indication(s) Technology Territory Revenue Source Marketer ZANAFLEX Muscle spasticity OCR U.S. Manufacturing Acorda; Actavis, Inc. CAPSULES Spheroidal Oral (capsules only) and (formerly Watson ZANAFLEX Drug Absorption Royalty Pharmaceutical) TABLETS System (SODAS) TIZANIDINE HYDROCHLORIDE (AB Rated to ZANAFLEX CAPSULES) AVINZA Chronic moderate OCR U.S. Manufacturing and Pfizer Inc. (‘‘Pfizer’’) to severe pain (SODAS) Royalty EMEND Nausea associated NanoCrystal Worldwide Manufacturing and Merck & Co. Inc. with Royalty (‘‘Merck’’) chemotherapy and surgery FOCALIN XR Attention Deficit OCR Worldwide Manufacturing and Novartis AG RITALIN LA Hyperactivity (SODAS) Royalty (‘‘Novartis’’) Disorder MEGACE ES Anorexia, Cachexia NanoCrystal U.S. Royalty Strativa associated Pharmaceuticals with AIDS (a business division of Par Pharmaceutical Companies, Inc.) LUVOX CR Obsessive- OCR U.S. Royalty Jazz compulsive (SODAS) Pharmaceuticals plc disorder (‘‘Jazz’’) RAPAMUNE Prevention of renal NanoCrystal Worldwide Manufacturing Pfizer transplant rejection NAPRELAN Various mild to OCR U.S. Manufacturing Shionogi moderate Intestinal Canada pain indications Protective Drug Absorption System (IPDAS) VERAPAMIL SR Hypertension OCR Licensed on Manufacturing and Kremers-Urban; VERELAN (SODAS) country/region Royalty (on select Cephalon; VERELAN PM basis throughout formulations) Aspen Pharma; VERAPAMIL PM the world Actavis, Inc. VERACAPS UNIVER DILZEM SR Hypertension OCR Licensed on Manufacturing and Cephalon; DILZEM XL and/or Angina (SODAS) country/region Royalty (for Kun-Wha DILTELAN basis throughout CARDIZEM Pharmaceutical Co. Ltd; CARDIZEM CD the world CD only) Sanofi; Valeant Pharmaceuticals International Inc. AFEDlTAB CR Hypertension OCR U.S. Manufacturing Actavis, Inc. (AB Rated (MXDAS) to ADALAT CC) ZOHYDRO ER Severe pain OCR U.S. Manufacturing and Zogenix, Inc. (SODAS) royalty Our key marketed products are expected to generate significant revenues for us in the near- and medium-term. They possess long patent lives, and we believe are singular or competitively advantaged